Lucid Diligence Brief: EpilepsyGTx $33m Series A
Lucid Diligence Brief: EpilepsyGTx $33m Series A Professional audiences only.…
Immunology Today—December 10, 2025
This week’s Immunology update highlights key advances in gene therapy,…
Respiratory Today—December 5, 2025
This week’s respiratory update highlights major developments across RSV…
Rare Disease Today—December 4, 2025
This week’s rare disease update highlights key regulatory designations, early…
Hematology Today—November 3, 2025
Catch the latest hematology news, featuring industry updates, clinical…
Lucid Diligence Brief: Lilly to acquire Adverum Biotechnologies
Lucid Diligence Brief: Lilly to acquire Adverum Biotechnologies Professional…
Cardiovascular Today - October 16, 2025
Get the latest on Cardiovascular this week, including key industry…
ESGCT 2025 Preview: Key Gene & Cell Therapy Highlights to Watch
ESGCT 2025 at a glance Ahead of ESGCT 2025, LucidQuest outlines the…
Cell and Gene Therapy Weekly News - September 18th 2025
Gene & Cell Therapy Update: Remedium–Lilly Obesity Pact, RMAT for…
Hematology Weekly News - September 1st 2025
🔬🩸 Hematology Updates: AML Survival Gains, Donor-Free Stem Cells, Gene Therapy…
Cell and Gene Therapy Weekly News - August 28th 2025
🧬 This Week in Gene & Cell Therapy: Rocket Pharma, RMATs, CAR-T…
Neuroscience Weekly News - August 27th 2025
🧠This Week in Neuroscience: AI-Redefined MS, $1B+ Epilepsy Deal, Home-Based…